Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 15/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | FSHR | P23945 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227430 | 1.00 | MCHR1 (0.68) | MCHR1HTR2CFSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL6899670 | 0.93 | MCHR1 (0.58) | MCHR1HTR2CALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL6895305 | 0.91 | MCHR1 (0.57) | MCHR1HTR2CALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL6894847 | 0.91 | MCHR1 (0.69) | MCHR1HTR2CALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL6893836 | 0.86 | MCHR1 (0.59) | MCHR1HTR2C | |
| SCHEMBL6918805 | 0.84 | MCHR1 (0.48) | MCHR1HTR2CALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL6925669 | 0.84 | MCHR1 (0.93) | MCHR1HTR2C | |
| SCHEMBL6894734 | 0.83 | MCHR1 (0.48) | MCHR1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL6898988 | 0.83 | MCHR1 (0.49) | MCHR1ALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL6925485 | 0.81 | MCHR1 (0.68) | MCHR1HTR2CALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001766-B1 | COMPOUNDS FOR THE TREATMENT OF CCR5-MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-04-09 | — | — | EP | claimed |
| US-6515027-B1 | Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 | SMITHKLINE BEECHAM CORP. | 2003-02-04 | — | — | US | claimed |
| EP-4143235-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | IncellDx, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222069-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | INCELLDX, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-1001766-B1 | COMPOUNDS FOR THE TREATMENT OF CCR5-MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6515027-B1 | Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 | SMITHKLINE BEECHAM CORP. | 2003-02-04 | — | — | US | disclosed |
| EP-1001766-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-1001766-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999001127-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-14 | — | — | WO | disclosed |